Search

Your search keyword '"Vekic J"' showing total 149 results

Search Constraints

Start Over You searched for: Author "Vekic J" Remove constraint Author: "Vekic J"
149 results on '"Vekic J"'

Search Results

51. Diabetes and Colorectal Cancer Risk: A New Look at Molecular Mechanisms and Potential Role of Novel Antidiabetic Agents

52. Atherogenic dyslipidemia and oxidative stress: a new look

53. COVID-19 increases mortality in hemodialysis patients: exploring links with inflammation and telomere attrition.

54. Sex-Specific Associations between Thyroid Status, Inflammation and Hemostasis Biomarkers in Patients with Subacute Thyroiditis.

55. Differences in HDL Remodeling during Healthy Pregnancy and Pregnancy with Cardiometabolic Complications.

56. Increased Odds of Metabolic Dysfunction-Associated Steatotic Liver Disease Are Linked to Reduced n-6, but Not n-3 Polyunsaturated Fatty Acids in Plasma.

57. The Effects of Pregestational Overweight and Obesity on Maternal Lipidome in Pregnancy: Implications for Newborns' Characteristics.

58. Obesity and dyslipidemia in early life: Impact on cardiometabolic risk.

59. Oxidative Stress, Atherogenic Dyslipidemia, and Cardiovascular Risk.

60. Obesity and Dyslipidemia: A Review of Current Evidence.

61. HDL Subclasses and the Distribution of Paraoxonase-1 Activity in Patients with ST-Segment Elevation Acute Myocardial Infarction.

63. The Role of Advanced Glycation End Products on Dyslipidemia.

64. The Prospect of Genomic, Transcriptomic, Epigenetic and Metabolomic Biomarkers for The Personalized Prevention of Type 2 Diabetes and Cardiovascular Diseases.

65. Alteration in Redox Status and Lipoprotein Profile in COVID-19 Patients with Mild, Moderate, and Severe Pneumonia.

67. Novel Pharmaceutical and Nutraceutical-Based Approaches for Cardiovascular Diseases Prevention Targeting Atherogenic Small Dense LDL.

68. Atherosclerosis Development and Progression: The Role of Atherogenic Small, Dense LDL.

69. A New Look at Novel Cardiovascular Risk Biomarkers: The Role of Atherogenic Lipoproteins and Innovative Antidiabetic Therapies.

70. Diabetes and Colorectal Cancer Risk: A New Look at Molecular Mechanisms and Potential Role of Novel Antidiabetic Agents.

71. The role of resistin in early preeclampsia prediction.

72. Revealing the Role of High-Density Lipoprotein in Colorectal Cancer.

73. Indirect reference intervals for haematological parameters in capillary blood of pre-school children.

75. Factors associated with oxidative stress status in pediatric patients with type 1 diabetes mellitus.

76. Heparin-binding epidermal growth factor (EGF)-like growth factor in pediatric patients with type 1 diabetes mellitus.

77. Increased Oxidized High-Density Lipoprotein/High-Density Lipoprotein-Cholesterol Ratio as a Potential Indicator of Disturbed Metabolic Health in Overweight and Obese Individuals.

78. Hashimoto Thyroiditis and Dyslipidemia in Childhood: A Review.

79. The association between lecithin-cholesterol acyltransferase activity and fatty liver index.

80. Association among resistin, adenylate cyclase-associated protein 1 and high-density lipoprotein cholesterol in patients with colorectal cancer: a multi-marker approach, as a hallmark of innovative predictive, preventive, and personalized medicine.

81. Obesity and dyslipidemia.

82. Association between proprotein convertase subtilisin/kexin 9 (PCSK9) and lipoprotein subclasses in children with type 1 diabetes mellitus: Effects of glycemic control.

83. Changes in lecithin: cholesterol acyltransferase, cholesteryl ester transfer protein and paraoxonase-1 activities in patients with colorectal cancer.

84. Association of Dyslipidemia, Oxidative Stress, and Inflammation With Redox Status in VLDL, LDL, and HDL Lipoproteins in Patients With Renal Disease.

85. Significance of LDL and HDL subclasses characterization in the assessment of risk for colorectal cancer development.

86. Activity of paraoxonase 1 (PON1) on HDL 2 and HDL 3 subclasses in renal disease.

87. Effects of co-existing autoimmune diseases on serum lipids and lipoprotein subclasses profile in paediatric patients with type 1 diabetes mellitus.

88. Preanalytical and analytical challenges in gas chromatographic determination of cholesterol synthesis and absorption markers.

89. Associations of lipoprotein subclasses and oxidative stress status in pulmonary and pulmonary plus extrapulmonary sarcoidosis.

90. Associations of Apgar score and size at birth with lipoprotein subclasses in juvenile obesity

91. The usefulness of advanced lipid and oxidative stress testing for diagnosis and management of low HDL-cholesterol phenotype: A case report.

92. Can non-cholesterol sterols and lipoprotein subclasses distribution predict different patterns of cholesterol metabolism and statin therapy response?

93. Relationship Between the Apolipoprotein E Genotype and LDL Particle Size in Patients With Obstructive Sleep Apnea.

94. Hypertension, lipoprotein subclasses and lipid transfer proteins in obese children and adolescents.

95. Oxidative stress and hemoglobin-cholesterol adduct in renal patients with different LDL phenotypes.

96. Association of small, dense low-density lipoprotein cholesterol and galectin-3 in patients with chronic kidney disease.

97. Smaller HDL particles are associated with absence of obstructive coronary artery disease in stable angina pectoris patients.

98. Association of glutathione-S-transferase gene polymorphism and lipoprotein subclasses in hemodialysis patients.

99. Interrelated cathepsin S-lowering and LDL subclass profile improvements induced by atorvastatin in the plasma of stable angina patients.

100. Distribution of low-density lipoprotein and high-density lipoprotein subclasses in patients with sarcoidosis.

Catalog

Books, media, physical & digital resources